BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 256 filers reported holding BRIDGEBIO PHARMA INC in Q2 2024. The put-call ratio across all filers is 0.32 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,187,249 | -30.9% | 125,829 | -15.7% | 0.62% | -20.9% |
| Q1 2024 | $4,613,944 | -8.6% | 149,222 | +19.4% | 0.78% | -13.5% |
| Q4 2023 | $5,045,604 | +39.1% | 124,984 | -9.1% | 0.91% | +32.2% |
| Q3 2023 | $3,626,191 | +164.0% | 137,512 | +72.2% | 0.69% | +157.3% |
| Q2 2023 | $1,373,816 | -42.8% | 79,873 | -44.9% | 0.27% | -44.9% |
| Q1 2023 | $2,401,663 | – | 144,853 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,989,412 | $130,095,000 | 49.65% |
| Kohlberg Kravis Roberts & Co. L.P. | 34,510,971 | $1,125,403,000 | 6.87% |
| SC US (TTGP), LTD. | 2,544,738 | $82,984,000 | 4.87% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $868,111,000 | 3.75% |
| Perceptive Advisors | 6,706,268 | $218,691,000 | 3.54% |
| Cormorant Asset Management, LP | 2,590,762 | $84,485,000 | 3.22% |
| Fernwood Investment Management, LLC | 145,100 | $4,732,000 | 2.34% |
| Grace Capital | 74,425 | $2,427,000 | 2.08% |
| HHLR ADVISORS, LTD. | 4,711,604 | $153,645,000 | 1.40% |
| AMERICAN INTERNATIONAL GROUP, INC. | 5,620,919 | $183,298,000 | 0.88% |